drugset / Trial / NCT00662649

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00662649

Phase 3 Completed 920 enrolled Novartis
RandomizedParallel-groupTriple-blindTreatment

Summary

This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).

Timeline

Start
2008-02
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg Oral
Subject Fingolimod Small molecule 1.25 mg Oral

Indications